{"id":62103,"date":"2026-04-01T20:32:29","date_gmt":"2026-04-01T12:32:29","guid":{"rendered":"https:\/\/flcube.com\/?p=62103"},"modified":"2026-04-01T20:32:30","modified_gmt":"2026-04-01T12:32:30","slug":"novo-nordisk-launches-wegovy-subscription-program-to-improve-obesity-treatment-access-and-affordability","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62103","title":{"rendered":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability"},"content":{"rendered":"\n<p><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced a new <strong>multi-month subscription program<\/strong> for <strong>Wegovy (semaglutide)<\/strong> that offers eligible self-pay patients a <strong>lower, predictable monthly price<\/strong> through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-details\">Program Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Launch Date<\/strong><\/td><td>March 31, 2026<\/td><\/tr><tr><td><strong>Initial Telehealth Partners<\/strong><\/td><td>Ro, WeightWatchers, LifeMD<\/td><\/tr><tr><td><strong>Upcoming Partners<\/strong><\/td><td>Hims &amp; Hers, Sesame, and others<\/td><\/tr><tr><td><strong>Annual Savings &#8211; Pill Form<\/strong><\/td><td>Up to USD 600\/year<\/td><\/tr><tr><td><strong>Annual Savings &#8211; Injection Form<\/strong><\/td><td>Up to USD 1,200\/year<\/td><\/tr><tr><td><strong>Subscription Term<\/strong><\/td><td>12-month commitment<\/td><\/tr><tr><td><strong>Eligibility<\/strong><\/td><td>Self-pay patients (contact telehealth providers for details)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Predictability<\/strong>: Addresses patient concerns about fluctuating out-of-pocket costs for chronic obesity treatment<\/li>\n\n\n\n<li><strong>Treatment Adherence<\/strong>: Designed to help patients start and maintain FDA-approved obesity therapy without financial interruption<\/li>\n\n\n\n<li><strong>Market Expansion<\/strong>: Expands access beyond traditional insurance channels to self-pay segment<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Strengthens Novo Nordisk&#8217;s direct-to-consumer strategy in the growing obesity treatment market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-telehealth-partnership-strategy\">Telehealth Partnership Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-initial-launch-partners\">Initial Launch Partners<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ro<\/strong>: Digital health platform specializing in prescription delivery<\/li>\n\n\n\n<li><strong>WeightWatchers<\/strong>: Established weight management brand expanding into medical interventions<\/li>\n\n\n\n<li><strong>LifeMD<\/strong>: Telehealth provider focused on chronic condition management<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-upcoming-partners\">Upcoming Partners<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hims &amp; Hers<\/strong>: Consumer-focused telehealth platform with strong digital marketing capabilities<\/li>\n\n\n\n<li><strong>Sesame<\/strong>: Transparent pricing healthcare marketplace<\/li>\n\n\n\n<li><strong>Additional partners<\/strong> expected to be announced in coming months<\/li>\n<\/ul>\n\n\n\n<p>The partnership model leverages existing telehealth infrastructure to streamline patient enrollment, eligibility verification, and medication delivery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-financial-implications\">Market Impact &amp; Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Treatment Market<\/strong>: U.S. obesity treatment market projected to exceed $100 billion by 2030, with GLP-1 therapies as primary growth driver<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Subscription model may pressure competitors to offer similar programs while maintaining premium pricing power<\/li>\n\n\n\n<li><strong>Revenue Stability<\/strong>: Multi-month commitments provide more predictable revenue streams compared to month-to-month prescriptions<\/li>\n\n\n\n<li><strong>Patient Retention<\/strong>: Improved affordability expected to increase long-term treatment duration and reduce discontinuation rates<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-context\">Competitive Landscape Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Leadership<\/strong>: Wegovy maintains dominant position in GLP-1 obesity treatment market despite supply constraints<\/li>\n\n\n\n<li><strong>Pipeline Competition<\/strong>: Eli Lilly&#8217;s Zepbound (tirzepatide) represents primary competitive threat with dual GIP\/GLP-1 mechanism<\/li>\n\n\n\n<li><strong>Access Strategy<\/strong>: Subscription program addresses key barrier of out-of-pocket costs that has limited broader market penetration<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding program implementation, market impact, and competitive dynamics for Wegovy. Actual results may differ due to risks including regulatory changes, competitive pressures, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[148,86],"class_list":["post-62103","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novo-nordisk","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers eligible self-pay patients a lower, predictable monthly price through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62103\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers eligible self-pay patients a lower, predictable monthly price through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62103\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T12:32:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T12:32:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability\",\"datePublished\":\"2026-04-01T12:32:29+00:00\",\"dateModified\":\"2026-04-01T12:32:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0102.webp\",\"keywords\":[\"Novo Nordisk\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62103#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62103\",\"name\":\"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0102.webp\",\"datePublished\":\"2026-04-01T12:32:29+00:00\",\"dateModified\":\"2026-04-01T12:32:30+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers eligible self-pay patients a lower, predictable monthly price through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62103\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62103#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers eligible self-pay patients a lower, predictable monthly price through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62103","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability","og_description":"Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers eligible self-pay patients a lower, predictable monthly price through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.","og_url":"https:\/\/flcube.com\/?p=62103","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T12:32:29+00:00","article_modified_time":"2026-04-01T12:32:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62103#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62103"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability","datePublished":"2026-04-01T12:32:29+00:00","dateModified":"2026-04-01T12:32:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62103"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62103#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp","keywords":["Novo Nordisk","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62103#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62103","url":"https:\/\/flcube.com\/?p=62103","name":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62103#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62103#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp","datePublished":"2026-04-01T12:32:29+00:00","dateModified":"2026-04-01T12:32:30+00:00","description":"Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers eligible self-pay patients a lower, predictable monthly price through select telehealth providers, designed to reduce cost uncertainty and improve adherence to FDA-approved obesity treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62103#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62103"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62103#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp","width":1080,"height":608,"caption":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62103#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62103"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62103\/revisions"}],"predecessor-version":[{"id":62105,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62103\/revisions\/62105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62104"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}